Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
50 hedge funds and large institutions have $213M invested in Albireo Pharma Inc in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 5 closing their positions.
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
161% more capital invested
Capital invested by funds: $81.8M → $213M (+$131M)
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
67% more funds holding
Funds holding: 30 → 50 (+20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.1M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$13.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$12.9M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.4M |
| 5 |
AG
Artal Group
Luxembourg
|
+$8.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.36M |
| 2 |
Renaissance Technologies
New York
|
-$953K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$907K |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$51K |
| 5 |
Morgan Stanley
New York
|
-$29.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$51K | -2,000 | Closed |
|
52
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -300 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$2K | -65 | Closed |
|
|
LTFS
54
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -33 | Closed |
|
ALBO Hedge Fund Activity: Q1 2018 in Review
50 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2018, worth a combined $213M — up 161% from $81.8M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ALBO positions and 5 closed out — a net gain of 20 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $21.1M. The largest seller was Sectoral Asset Management, cutting an estimated $2.36M.
- 50 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2018, up from 30 in Q4 2017.
- Funds reported $213M of Albireo Pharma Inc stock for Q1 2018, up 161% quarter-over-quarter.
- 25 funds opened new Albireo Pharma Inc positions in Q1 2018 and 5 closed out, a net change of +20 holders.
- The largest Albireo Pharma Inc buyer in Q1 2018 was Fidelity Investments, an estimated $21.1M added.
- The largest Albireo Pharma Inc seller in Q1 2018 was Sectoral Asset Management, an estimated $2.36M sold.
Based on aggregated 13F filings for Q1 2018.